- Corporate
- The share
- Press releases
- Financial calendar
- Financial reports
- Financial reports – ESEF
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- Code of Conduct
- Environmental Policy
- Code of Conduct for Suppliers
- Privacy policy
- Contact us
- Subscribe
- Thank you
- Error
XVIVO gains regulatory approval in China for PERFADEX® Plus – the global gold standard for lung preservation
XVIVO Perfusion AB has gained regulatory approval in China from NMPA (National Medical Products Administration) for the company’s ‘ready-to-use’ product PERFADEX Plus. China is the second largest transplant market in the world. It is also currently the fastest growing lung transplant market with an average annual growth rate of 28 percent during the six-year period 2015-20201*. In 2020, 513 lung transplants were performed. Due to the increased need, the number of clinics authorized to perform lung transplants has grown from 20 in 2016 to 50 in 2021.
PERFADEX Plus is a ready-to-use version of PERFADEX which has been the gold standard for over 20 years. PERFADEX and PERFADEX Plus have been used in more than 65,000 lung transplantations and is used by more than 90 percent of all lung transplant clinics in the world.
A lung transplant is the last resort for patients with end-stage lung disease. It is the only treatment option available for patients with a life expectancy estimated to be less than 2 years who have exhausted all other treatment alternatives. PERFADEX Plus is used for the flushing, cold static storage and transportation of donated lungs.
“By introducing the new, ready-to-use, version of the product – PERFADEX Plus – on the Chinese market we are strengthening our offer to all lung transplant clinics”, says Raymond Wood XVIVO General Manager in China.
“We are already active in China, and with this product launch we can intensify our presence. China is strategically very important for XVIVO and within a timeframe of 5 years we will expand our product offer to include all major organs. This is an important first step.” says Dag Andersson XVIVO CEO.
February 2, 2022
Gothenburg
Dag Andersson, CEO
XVIVO Perfusion AB (publ)
*Global Observatory on Donation and Transplantation (www.transplant-observatory.org)
For further information, please contact:
Dag Andersson, CEO, +46 76 643 30 31, e-mail: dag.andersson@xvivogroup.com
Kristoffer Nordström, CFO, +46 73 519 21 64, e-mail: kristoffer.nordstrom@xvivogroup.com
About Us
Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs – so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.
